The study, which is still ongoing, also provided support for a separate Phase 2/3 trial of a targeted treatment for the neurodevelopmental disorder.
The international team of researchers also examined the genetic ties between personality traits and psychiatric disorders.
The two firms are collaborating on a system to share genotypic, phenotypic, and treatment outcomes data with physicians on a mobile-device network.
Using CNV profiles for more than 40,000 individuals with or without schizophrenia, researchers got a refined look at gains and losses linked to the condition.
The findings run counter to the traditional understanding of tau's role in Alzheimer's, which holds that modified forms of the protein help drive the disease.
In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.
Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.
The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.
Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.